Stine Krag Brunvold 12/14/22 Stine Krag Brunvold 12/14/22

NMD Pharma Receives IND Clearance to Start a Phase II Clinical Trial of NMD670 for the Treatment of Symptoms of Spinal Muscular Atrophy Type 3

Stine Krag Brunvold 10/11/22 Stine Krag Brunvold 10/11/22

NMD Pharma Reports Positive Top-Line Data from a Phase I/IIa Clinical Trial of NMD670 in Patients with Myasthenia Gravis

Stine Krag Brunvold 9/27/22 Stine Krag Brunvold 9/27/22

Stine Krag Brunvold 5/10/22 Stine Krag Brunvold 5/10/22

Stine Krag Brunvold 5/3/22 Stine Krag Brunvold 5/3/22

Stine Krag Brunvold 2/15/22 Stine Krag Brunvold 2/15/22

Stine Krag Brunvold 7/8/21 Stine Krag Brunvold 7/8/21

Stine Krag Brunvold 6/30/21 Stine Krag Brunvold 6/30/21

Stine Krag Brunvold 6/1/21 Stine Krag Brunvold 6/1/21

Stine Krag Brunvold 11/30/20 Stine Krag Brunvold 11/30/20

It all begins with an idea.

Stine Krag Brunvold 11/30/20 Stine Krag Brunvold 11/30/20

It all begins with an idea.

Stine Krag Brunvold 10/6/20 Stine Krag Brunvold 10/6/20

It all begins with an idea.

Stine Krag Brunvold 7/15/20 Stine Krag Brunvold 7/15/20

It all begins with an idea.

Stine Krag Brunvold 3/23/18 Stine Krag Brunvold 3/23/18

It all begins with an idea.